Human Genes that Influence HIV-1 Replication, Pathogenesis, and Immunity in IVDUs

影响 IVDU 中 HIV-1 复制、发病机制和免疫的人类基因

基本信息

  • 批准号:
    8893936
  • 负责人:
  • 金额:
    $ 82.49万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-08-01 至 2016-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Despite 30 years of AIDS research, there is still no robust, reverse-genetic system for studying the in vivo function of human genes that influence HIV-1 replication, pathogenesis, and immunity. As the number of such genes skyrockets, including genes that determine rates of HIV-1 acquisition and disease progression among intravenous drug users, the need for such technology has never been greater. This proposal addresses technical hurdles that must be overcome before such an experimental system can be realized. RNAi transformed the functional assessment of human genes, but lack of reproducibility and inability to assess allelic variants limit utility. Mouse gene knockout technology is unsurpassed at unambiguous assignment of function to particular mammalian genes. Unfortunately, many human genes lack simple mouse orthologues, including APOBEC3G and TRIMS, two genes that restrict HIV-1 infection among intravenous drug users. Worse, HIV-1 does not replicate in mouse cells. The project proposed here will develop tools for targeted gene replacement by homologous recombination in cells of the human immune system, and for functional assessment of these modified cells within the context of an in vivo model of HIV-1 transmission, replication, immunity, and AIDS pathogenesis. Towards this end, ongoing, cutting-edge technical developments from several fields will be exploited, including human embryonic stem cells and somatic cell reprogramming, murine immune system substitution with human counterparts, lentiviral vectors that permit efficient delivery of DNA to transfection-resistant cells, and designer nucleases to stimulate homologous recombination. Development of a perpetual source of isogenic, human hematopoietic stem cells that can be genetically-modified in a controlled fashion, and used to generate an immune system within an in vivo experimental model, will permit us to draw firm conclusions concerning the function of particular human genes - or of particular alleles - in hematopoietic development, immune function, and HIV-1 replication and pathogenesis, all within a setting of substances of abuse.
描述(由申请人提供):尽管艾滋病研究已有30年,但仍然没有强大的反向遗传系统来研究影响HIV-1复制、发病机制和免疫力的人类基因的体内功能。随着这些基因的数量激增,包括决定静脉注射吸毒者中HIV-1感染率和疾病进展的基因,对这种技术的需求从未如此之大。该提案解决了在实现这种实验系统之前必须克服的技术障碍。RNAi改变了人类基因的功能评估,但缺乏可重复性和无法评估等位基因变异限制了实用性。小鼠基因敲除技术在明确指定特定哺乳动物基因的功能方面是无与伦比的。不幸的是,许多人类基因缺乏简单的小鼠基因, 直系同源基因,包括APOBEC 3G和TRIMS,这两个基因限制了静脉注射吸毒者中的HIV-1感染。更糟糕的是,HIV-1不能在小鼠细胞中复制。这里提出的项目将开发工具,通过同源重组在人类免疫系统细胞中进行靶向基因置换,并在HIV-1传播,复制,免疫和艾滋病发病机制的体内模型的背景下对这些修饰细胞进行功能评估。 为此,来自多个领域的正在进行的尖端技术开发将在 利用,包括人类胚胎干细胞和体细胞重编程,小鼠 用人对应物替换免疫系统,允许有效 将DNA递送至抗转染细胞,以及设计核酸酶以刺激同源重组。开发可以以受控方式进行遗传修饰并用于在体内实验模型中产生免疫系统的等基因人类造血干细胞的永久来源,将使我们能够得出关于特定人类基因或特定等位基因在造血发育、免疫功能和HIV-1复制和发病机制中的功能的明确结论,都是在滥用药物的情况下。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JEREMY LUBAN其他文献

JEREMY LUBAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JEREMY LUBAN', 18)}}的其他基金

Insight into the Ebola virus glycoprotein fusion mechanism gleaned from the 2013-2016 epidemic GP-A82V variant
从2013-2016年流行的GP-A82V变种中洞察埃博拉病毒糖蛋白融合机制
  • 批准号:
    10334830
  • 财政年份:
    2021
  • 资助金额:
    $ 82.49万
  • 项目类别:
Insight into the Ebola virus glycoprotein fusion mechanism gleaned from the 2013-2016 epidemic GP-A82V variant
从2013-2016年流行的GP-A82V变种中洞察埃博拉病毒糖蛋白融合机制
  • 批准号:
    10541247
  • 财政年份:
    2020
  • 资助金额:
    $ 82.49万
  • 项目类别:
Insight into the Ebola virus glycoprotein fusion mechanism gleaned from the 2013-2016 epidemic GP-A82V variant
从2013-2016年流行的GP-A82V变种中洞察埃博拉病毒糖蛋白融合机制
  • 批准号:
    10077831
  • 财政年份:
    2020
  • 资助金额:
    $ 82.49万
  • 项目类别:
The HUSH complex in HIV-1 latency
HIV-1潜伏期中的HUSH复合体
  • 批准号:
    10439610
  • 财政年份:
    2019
  • 资助金额:
    $ 82.49万
  • 项目类别:
The HUSH complex in HIV-1 latency
HIV-1潜伏期中的HUSH复合体
  • 批准号:
    10656350
  • 财政年份:
    2019
  • 资助金额:
    $ 82.49万
  • 项目类别:
The HUSH complex in HIV-1 latency
HIV-1潜伏期中的HUSH复合体
  • 批准号:
    10176390
  • 财政年份:
    2019
  • 资助金额:
    $ 82.49万
  • 项目类别:
Next generation hybrid nucleases for precise excision of latent HIV-1 provirus
用于精确切除潜伏 HIV-1 原病毒的下一代杂交核酸酶
  • 批准号:
    9010933
  • 财政年份:
    2015
  • 资助金额:
    $ 82.49万
  • 项目类别:
Boosting cell-intrinsic innate immune recognition of HIV-1 by dendritic cells
增强树突状细胞对 HIV-1 的细胞内在先天免疫识别
  • 批准号:
    9241321
  • 财政年份:
    2014
  • 资助金额:
    $ 82.49万
  • 项目类别:
Boosting cell-intrinsic innate immune recognition of HIV-1 by dendritic cells
增强树突状细胞对 HIV-1 的细胞内在先天免疫识别
  • 批准号:
    8705952
  • 财政年份:
    2014
  • 资助金额:
    $ 82.49万
  • 项目类别:
Boosting cell-intrinsic innate immune recognition of HIV-1 by dendritic cells
增强树突状细胞对 HIV-1 的细胞内在先天免疫识别
  • 批准号:
    8831600
  • 财政年份:
    2014
  • 资助金额:
    $ 82.49万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 82.49万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 82.49万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 82.49万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 82.49万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 82.49万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 82.49万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 82.49万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 82.49万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 82.49万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 82.49万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了